Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03891524 · ClinicalTrials.gov registry record · Phase 2
A Study of JNJ-70033093 (BMS-986177) Versus Subcutaneous Enoxaparin in Participants Undergoing Elective Total Knee Replacement Surgery
A Phase 2 study, sponsored by Janssen Research & Development.
- Completed
- Registry status
- Phase 2
- Development phase
- 1,242
- Enrollment target
NCT03891524: Completed Phase 2 study, sponsored by Janssen Research & Development.
NCT03891524 is a Phase 2 study that has completed, run by Janssen Research & Development. The registered enrollment target is 1,242 participants, above the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (834% higher). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT03891524, a Phase 2 study, has completed, sponsored by Janssen Research & Development.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 1,242 participants
- Enrollment target
Study Summary
The purpose of this study is to determine the efficacy of JNJ-70033093 in preventing total venous thromboembolism (VTE) events (proximal and/or distal deep vein thrombosis \[DVT\] \[asymptomatic confirmed by venography assessment or objectively confirmed symptomatic\], nonfatal pulmonary embolism \[PE\], or any death) during the treatment period.
Primary Outcome
Total VTE was defined as the composite of clinical events committee (CEC)-adjudicated proximal and/or distal Deep Vein Thrombosis (DVT) (asymptomatic confirmed by venography assessment of the operated leg or objectively confirmed symptomatic), nonfatal pulmonary embolism (PE), or any death.
Interventions
- DRUG Placebo
- DRUG JNJ-70033093 25 mg
- DRUG JNJ-70033093 50 mg
- DRUG JNJ-70033093 100 mg
- DRUG JNJ-70033093 200 mg
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 1,242 participants |
| Start Date | 2019-06-17 |
| Est. Completion | 2021-04-06 |
| Phase | Phase 2 |
What the finished NCT03891524 record still lists
NCT03891524 is an interventional study that assigns participants to a tested intervention. Its 1,242 participants enrollment target places it among the larger protocols in the corpus, above the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (834% higher).
The record links to 0 conditions, and to 5 interventions - of which Placebo is the first listed.
NCT03891524 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT03891524 about?
NCT03891524 is a clinical study titled "A Study of JNJ-70033093 (BMS-986177) Versus Subcutaneous Enoxaparin in Participants Undergoing Elective Total Knee Replacement Surgery". The purpose of this study is to determine the efficacy of JNJ-70033093 in preventing total venous thromboembolism (VTE) events (proximal and/or distal deep vein thrombosis \[DVT\] \[asymptomatic confirmed by venography assessment or objectively confirmed symptomatic\], nonfatal pulmonary embolism \[...
What is the current status of trial NCT03891524?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 1,242 participants. The study started on 2019-06-17. Estimated completion is 2021-04-06.
What interventions are being tested in trial NCT03891524?
The interventions under investigation include: Placebo (DRUG), JNJ-70033093 25 mg (DRUG), JNJ-70033093 50 mg (DRUG), JNJ-70033093 100 mg (DRUG), JNJ-70033093 200 mg (DRUG).
Who is sponsoring clinical trial NCT03891524?
This trial is sponsored by Janssen Research & Development, which has 593 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT03891524's enrollment target sits among peer trials
1,242 16th of 2000 higher than 1,985 of 2,000 other Phase 2 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 2 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT06368245 · 1,244 participants
Durability of Suppl. Rod Constructs-SuppleMentAry Rod Technique for Long-segment Posterior Instrumented Spinal Fusions
- NCT02743858 · 1,250 participants
Lymphedema Surveillance Study
- NCT04670874 · 1,250 participants
Quality of Life in Cutaneous Lymphoma Patients Using the Skindex29
- NCT04807868 · 1,250 participants
AdventHealth Research Institute Non-Alcoholic Fatty Liver Disease Biobank and Registry (AVAIL)
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI